Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Lung cancers with oncogenic mutations in the epidermal growth factor receptor (EGFR) invariably acquire resistance to tyrosine kinase inhibitor (TKI) treatment. Vulnerabilities of EGFR TKI-resistant cancer cells that could be therapeutically exploited are incompletely understood. Here, we describe a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Rep
Autori principali: Marcar, Lynnette, Bardhan, Kankana, Gheorghiu, Liliana, Dinkelborg, Patrick, Pfäffle, Heike, Liu, Qi, Wang, Meng, Piotrowska, Zofia, Sequist, Lecia V., Borgmann, Kerstin, Settleman, Jeffrey E., Engelman, Jeffrey A., Hata, Aaron N., Willers, Henning
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624074/
https://ncbi.nlm.nih.gov/pubmed/31216465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2019.05.058
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi